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In acute myeloid leukemia (AML),MLL (KMT2A) rearrangements are among the most
frequent chromosomal abnormalities; however, knowledge of the genetic landscape ofMLL-
rearranged AML is limited. In this study, we performed whole-exome sequencing (n 5 9)
and targeted sequencing (n 5 56) of samples from pediatric MLL-rearranged AML patients
enrolled in the Japanese Pediatric Leukemia/Lymphoma Study Group AML-05 study.
Additionally, we analyzed 105 pediatric t(8;21) AML samples and 30 adult MLL-rearranged
AML samples. RNA-sequencing data from 31 patients published in a previous study were
also reanalyzed. As a result, we identiﬁed 115 mutations in pediatricMLL-rearranged AML
patients (2.1 mutations/patient), with mutations in signaling pathway genes being the most
frequently detected (60.7%). Mutations in genes associated with epigenetic regulation
(21.4%), transcription factors (16.1%), and the cohesin complex (8.9%) were also commonly
detected. Novel CCND3 mutations were identiﬁed in 5 pediatric MLL-rearranged AML
patients (8.9%) and 2 adult MLL-rearranged AML patients (3.3%). Recurrent mutations of
CCND1 (n 5 3, 2.9%) and CCND2 (n 5 8, 7.6%) were found in pediatric t(8;21) AML patients,
whereas no CCND3mutations were found, suggesting that D-type cyclins exhibit a subtype-
speciﬁc mutation pattern in AML. Treatment of MLL-rearranged AML cell lines with
CDK4/6 inhibitors (abemaciclib and palbociclib) blocked G1 to S phase cell-cycle progres-
sion and impaired proliferation. Pediatric MLL-MLLT3–rearranged AML patients with
coexisting mutations (n 5 16) had signiﬁcantly reduced relapse-free survival and overall
survival compared with those without coexisting mutations (n 5 9) (P 5 .048 and .046,
respectively). These data provide insights into the genetics of MLL-rearranged AML and
suggest therapeutic strategies.
Submitted 2 April 2018; accepted 13 September 2018. DOI 10.1182/
bloodadvances.2018019398.
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Introduction
Acute myeloid leukemia (AML) is a genetically and clinically hetero-
geneous disease characterized by expansion of undifferentiated
myeloid precursor cells.1-3 Recurrent chromosomal and genetic
abnormalities, including t(8;21), inv(16), t(15;17), and FLT3-internal
tandem duplication (FLT3-ITD), are well-established markers for risk-
stratified therapy in AML4,5; however, relapse remains common, and
patients with relapsed AML have a poor prognosis.6 Recent genome-
wide analyses revealed several recurrently mutated genes in AML,
including DNMT3A, IDH1, IDH2, splicing factors, and cohesin
complex genes7-9; however, few of these driver mutations have been
developed as therapeutic targets to date. Moreover, because of the
high level of genetic heterogeneity in AML, the clinical impact of driver
mutations in each AML subtype remains unclear.
Rearrangements involving the MLL (mixed-lineage leukemia; official
symbol, KMT2A) gene are among the most common chromosomal
abnormalities in AML; these rearrangements are more common in
pediatric AML (20%-24%), particularly infant AML (38%), than in adult
AML (5%-10%),10-13 and .60 different MLL partner genes have
been identified.14 AlthoughMLL rearrangement has been regarded as
a marker for poor prognosis in patients with AML, a recent study
showed that the prognoses of patients with these changes vary
considerably according to the MLL fusion partner. For example,
pediatric AML patients with t(1;11)(q21;q23)/MLL-MLLT11 have
favorable prognoses, whereas those with t(6;11)(q27;q23)/MLL-
MLLT4(AF6), t(4;11)(q21;q23)/MLL-AFF1, t(10;11)(p12;q23)/MLL-
MLLT10(AF10), and t(10;11)(p11.2;q23)/MLL-ABI1 have poor
prognoses.15 The number of coexisting mutations is lower in MLL-
rearranged AML than in other AML subtypes.2,13 RAS pathway
mutations are well described; however, little is known about the
prognostic significance of coexisting mutations in MLL-rearranged
AML.16-18 A recent study of adult MLL-rearranged AML revealed
novel somatic mutations in the transcription factor gene SPI1.18
Nevertheless, the genetic landscape of pediatric MLL-rearranged
AML has yet to be fully elucidated, and further investigations are
required to identify novel recurrent mutations and support improved
therapeutic approaches in pediatric MLL-rearranged AML.
In this study, we identified recurrent mutations in CCND3, which
encodes cyclin D3, in MLL-rearranged AML. Cyclins are cofactors
that bind to cyclin-dependent kinases (CDKs), allowing cell-cycle
progression. D-type cyclins form complexes with CDK4/6, which
promote cell-cycle progression from G1 to S phase by phosphor-
ylation of retinoblastoma protein (Rb).19,20 There are 3 D-type
cyclins: cyclin D1 (encoded by CCND1), cyclin D2 (encoded by
CCND2), and cyclin D3. Aberrant cell-cycle regulation mediated by
deregulation of D-type cyclins is a major characteristic of cancer.21
In AML, recurrent mutations in CCND1 and CCND2 in t(8;21) AML
were reported in previous studies22,23; however, recurrent CCND3
mutations have not been reported. A recent study showed that
patients with deregulation of D-type cyclins may benefit from
treatment with the CDK4/6 inhibitor24; therefore, we also examined
the effectiveness of CDK4/6 inhibitors inMLL-rearranged AML cells.
Methods
Patients and study protocol
The AML-05 study is a Japanese nationwide multi-institutional study
of children (age ,18 years) with de novo AML conducted by the
Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG) in
which 485 patients were enrolled between 1 November 2006 and
31 December 2010. The trial was registered with the UMIN Clinical
Trials Registry (#UMIN000000511; http://www.umin.ac.jp/ctr/
index.htm), and details of the schedules and treatment regimens
have been described previously.25 AML was diagnosed via a central
review system. The study was conducted in accordance with the
principles set down in the Declaration of Helsinki and approved by
the ethics committees of all participating institutions. All patients, or
their parents/guardians, provided written informed consent.
Whole-exome sequencing
Whole-exome sequencing was performed as previously reported.26
Whole-exome capture was accomplished by liquid phase hybrid-
ization of sonicated genomic DNA using a bait complementary RNA
library (SureSelect Human ALL Exon V5 or V5 Inc RNA 5 kit; Agilent
Technologies, Santa Clara, CA) following the manufacturer’s
protocol. Massively parallel sequencing of the captured targets
was performed using a HiSeq 2000/2500 sequencing system
(Illumina, San Diego, CA) with the paired-end 126- to 133-bp read
option, following the manufacturer’s instructions. Sequencing reads
were aligned to hg19 using BWA-mem version 0.5.8 with default
parameters. Details of the methods used to detect candidate
somatic mutations using EBcell (Empirical Bayesian mutation
Calling)27 are presented in supplemental Methods.
Targeted sequencing
In total, 338 gene targets were examined for gene mutations in the
56 MLL-rearranged AML pediatric cases using targeted capture
sequencing and selected if they were (1) known driver genes in
myeloid malignancies or other neoplasms, (2) associated with
myeloid malignancies, (3) mutated as detected by whole-exome
sequencing in this study, and (4) therapeutically targetable.
Sample preparation, sequencing, and data analyses were performed
using the same approach as for whole-exome sequencing. Target
enrichment was performed using a SureSelect custom kit (Agilent
Technologies), which is designed to capture all coding exons of the
above 338 genes and 1216 single-nucleotide polymorphisms for copy-
number analysis. Similarly, CCND1, CCND2, and CCND3 were also
captured and sequenced in samples from 105 pediatric cases
with t(8;21)/RUNX1-RUNX1T1 AML and 30 adult patients with
MLL-rearranged AML. Detailed methods for detecting candidate
somatic mutations are presented in supplemental Methods.
Detection of copy-number alterations
Copy-number analysis was performed as previously reported28 using
an in-house pipeline (Y. Shiozawa and S.O., manuscript in preparation)
in which the total number of reads covering each bait region and the
allele frequency of heterozygous single-nucleotide polymorphisms
detected by targeted sequencing were used as input data.
Sanger sequencing and deep sequencing
First, polymerase chain reaction (PCR) was performed using a pair
of primers targeting the PEST domain–encoding region of the
CCND3 gene (forward, 59-TGAGAACTAAAGAGCGATTCC-
TGG-39; reverse, 59-CTTTGTGAAGGGGGAACAGACG-39). Re-
actions were performed in a volume of 20 mL containing 2 mL
103 PCR buffer for KOD plus polymerase, 2 mL 29-deoxynucleoside
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59-triphosphate mix (2 mM), 1.2 mL MgSO4 (25 mM), 0.4 mL KOD
plus polymerase (1 U/mL) (Toyobo, Osaka, Japan), 0.2 mL each
primer (100 mM; Invitrogen, San Diego, CA), and 20 ng template
DNA. Reactions were carried out in a Veriti 96-Well Thermal Cycler
(Applied Biosystems, Foster City, CA) using a touchdown PCR
protocol (1 cycle of 96°C for 2minutes; 3 cycles of 96°C for 10 seconds,
64°C for 10 seconds, and 70°C for 30 seconds; 3 cycles of 96°C for
10 seconds, 61°C for 10 seconds, and 70°C for 30 seconds; 3 cycles of
96°C for 10 seconds, 58°C for 10 seconds, and 70°C for 30 seconds;
35 cycles of 96°C for 10 seconds, 57°C for 10 seconds, and 70°C
for 30 seconds; and 1 cycle of 70°C for 5 minutes). PCR products
were analyzed by agarose gel electrophoresis and purified using a
FastGene Gel/PCR Extraction Kit (NIPPON Genetics, Tokyo, Japan)
according to the manufacturer’s instructions. The sequences of
purified PCR products were determined by direct sequencing using
a forward primer (59-CCAGACTTCCCCATGTGTTGG-39) and a
BigDye Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems)
on a 3130xl Genetic Analyzer (Applied Biosystems). For deep
sequencing, PCR amplicons were sonicated and prepared using a
NEBNext Ultra DNA Library Prep Kit for Illumina (New England
Biolabs). Sequencing was performed using a MiSeq platform with the
77-bp paired-end read option.
Compounds
Palbociclib (PD0332991) and abemaciclib (LY2835219) were
obtained from AdooQ BioScience (Irvine, CA). Both compounds
were dissolved in dimethyl sulfoxide (DMSO).
Cell culture
ML-2, MV4-11, and MOLM-13 cell lines were obtained from
the German Collection of Microorganisms and Cell Cultures
(Braunschweig, Germany). THP-1 and NOMO-1 cell lines were
obtained from the Japanese Collection of Research Bioresources
Cell Bank (Ibaraki, Japan). All cell lines were cultured in RPMI 1640
medium containing 10% fetal bovine serum and 1% penicillin/
streptomycin under 5% CO2 and 95% air at 37°C.
Cell proliferation assay
Cells (23 105/mL) were cultured in the presence of DMSO (control),
palbociclib (500 nM), or abemaciclib (500 nM). Data are presented as
the mean 6 standard error of 3 independent experiments.
Cell-cycle analysis
Cells (2 3 105/mL) were treated with DMSO (control), palbociclib
(500 nM), or abemaciclib (500 nM) for 24 hours. Then, cells were
stained with propidium iodide and analyzed using a FACS Canto II
flow cytometer (BD Biosciences, San Jose, CA).
Immunoblot analysis
Cells were washed with PBS and then lysed in RIPA buffer
containing a protease inhibitor cocktail (Nakalai, Kyoto, Japan). After
centrifugation, the protein content in supernatants was measured
using a DC Protein Assay (Bio-Rad Laboratories, Hercules, CA).
Whole-cell lysates containing equal amounts of total protein were
separated on 10% sodium dodecyl sulfate polyacrylamide gels and
then transferred to Immobilon-P transfer membranes (Merck,
Darmstadt, Germany). Membranes were blocked with Blocking
One reagent (Nakalai) for 1 h, followed by incubation overnight at
4°C with an anti-cyclin D3 antibody (1/1000; K0013-3; MBL,
Nagoya, Japan) or an anti-GAPDH antibody (1/3000; sc-47724;
Santa Cruz Biotechnology, Santa Cruz, CA). After washing
thoroughly in Tris-buffered saline with Tween 20, membranes
were incubated with horseradish peroxidase–conjugated whole
anti-mouse immunoglobulin G (1/4000; NA931; GE Healthcare
Bio-Sciences) for 1 hour at room temperature. Immunoreactive
proteins were detected using a horseradish peroxidase Novex
ECL Chemiluminescent Substrate Regent Kit (Invitrogen). Signals
were captured, and the intensities of bands were quantified using
a ChemiDoc XRS System (Bio-Rad Laboratories).
RNA interference
Small interfering RNA (siRNA) against human cyclin D3 transcript
(sc-35136) and the nontargeting siRNA (sc-37007) were purchased
from Santa Cruz Biotechnology. THP-1 cells (4 3 104/mL) were
cultured in RPMI 1640 medium containing 10% fetal bovine serum
without 1% penicillin/streptomycin at 37°C. After 1 day, THP-1 cells
were transfected with siRNA/Lipofectamine RNAiMAX (Invitrogen)
complexes diluted in Opti-MEM Reduced Serum Medium (Gibco)
(final siRNA concentration, 50 nM) according to the manufacturer’s
protocol. Two days after transfection, whole-cell lysates were
prepared to determine knockdown efficiency by immunoblot analysis.
Four days after transfection, THP-1 cells were collected for cell-cycle
analysis by fluorescence-activated cell sorting.
Statistical analysis
Survival analyses were performed using the Kaplan-Meier method,
and groups were compared using an unstratified log-rank test.
Continuous variables were compared using the Student t test.
Results
Spectrum of mutations and copy-number alterations
in pediatric MLL-rearranged AML
First, we analyzed paired AML tumor and germline samples from
9 pediatric MLL-rearranged AML patients enrolled in the JPLSG
AML-05 study by whole-exome sequencing. Five of the patients
were included in our previous study (supplemental Figure 1).29 In total,
52 mutations (mean, 5.8 mutations/patient) were identified (supple-
mental Table 1; supplemental Figure 2), including known mutational
targets in AML, such as genes associated with signaling activation
(FLT3 and BRAF), epigenetic regulation (SETD2 and BCORL1), and
encoding transcription factors (WT1). Moreover, CCND3, which is a
well-known driver gene in lymphomas,30 was mutated in 1 patient.
Next, we analyzed 56 samples from patients with pediatric MLL-
rearranged AML enrolled in the JPLSG AML-05 study using targeted
sequencing. Patient characteristics are presented in Table 1. The
median age of patients was 3.0 years, which is consistent with data
demonstrating thatMLL-rearranged AML is frequent in infants.13 Over
half of patients were classified in the M5a category (54%), followed by
M4 (23%), M1 (7%), M5b (5%), M2 (2%), M4Eo (2%), and RAEB-T
(2%). Among fusion types, MLL-MLLT3 was the most frequent
(45%), followed by MLL-MLLT10 (20%), MLL-ELL (18%), MLL-
MLLT1 (9%), andMLL-MLLT4 (AF6) (5%). We selected 338 genes,
including CCND3, for targeted sequencing (supplemental Table 2).
The driver or recurrent mutations detected by targeted sequencing
are presented according to fusion type in Figure 1. Detailed results of
targeted sequencing are provided in supplemental Table 3.
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We identified 115 mutations (mean, 2.1 mutations/patient), with
the following mutations in signaling pathway genes being the most
frequently detected (60.7%): FLT3 (n5 13, 23.2%), NRAS (n5 11,
19.6%),KRAS (n5 9, 16.1%),PTPN11 (n5 6, 10.7%),CBL (n5 5,
8.9%), and BRAF (n 5 1, 1.8%). Mutations in genes associated with
epigenetic regulation (SETD2, ASXL1, ASXL2, BCOR, BCORL1,
KDM6A,CREBBP, and EP300) (21.4%), transcription factors (SPI1,
WT1, MECOM, GATA2, and RUNX1) (16.1%), and the cohesin
complex (STAG2, RAD21, and SMC3) (8.9%) were also commonly
detected. Interestingly, allMLL-ELL patients had at least 1 mutation of
a signaling pathway gene, and all 3 STAG2mutations were restricted
to MLL-ELL patients, suggesting that the distribution of coexisting
mutations differs according to MLL fusion partner.
Copy-number alterations were also infrequent in MLL-rearranged
AML, with trisomy 8 being the most frequently detected (identified
in 6 cases; Figure 1; supplemental Figure 3), which is consistent
with previous reports showing that trisomy 8 is among the most
common cytogenetic aberrations in pediatric AML.31,32
Recurrent CCND3 mutations in pediatric and adult
MLL-rearranged AML
We identified 8 mutations in CCND3, which encodes cyclin D3,
in 5 pediatric MLL-rearranged AML patients (8.9%). Detailed
information regarding patients with CCND3 mutations is presented
in Table 2. All mutations were clustered in the PEST domain
(Figure 2A), which is found in short-lived proteins and plays a role
in their degradation.33 Four of the 8 mutations were R271fs, which
is a known hot-spot mutation in lymphoid malignancies.30,34-38
To determine whether CCND3 mutations were also present in adult
MLL-rearranged AML, we analyzed 30 adult MLL-rearranged AML
samples for CCND3 mutations by targeted sequencing (patient
information provided in supplemental Table 4). RNA-sequencing data
from 31 patients published in a previous study were also reanalyzed.18
CCND3mutations affecting the PEST domain were detected in 2 out
of 61 samples (3.3%) (Figure 2A). In total, 4 out of 7 patients (57.1%)
with CCND3 mutations were detected among those with MLL-
ELL–positive AML. All CCND3 mutations identified in our cohort
were confirmed by Sanger sequencing or deep sequencing
(supplemental Figure 4). Mutations of the PEST domain of CCND3
elevate the stability of cyclin D3 protein and promote cell pro-
liferation30; therefore, these results suggest that the stabilization of
cyclin D3 is important in both pediatric and adultMLL-rearranged AML.
Mutations of D-type cyclins exhibit a disease
subtype–specific pattern in AML
Mutations of the other D-type cyclins (CCND1 and CCND2)
have been reported in t(8;21) AML22,23; therefore, we also
searched for mutations in CCND1, CCND2, and CCND3 by
targeted sequencing of samples from pediatric AML patients
with t(8;21)/RUNX1-RUNX1T1 (n 5 105). CCND1 mutations
(n 5 3; 2.9%) and CCND2 mutations (n 5 8; 7.6%) were detected
in t(8;21) patients; however, no mutations of CCND3 were
found in this group (Figure 2B; supplemental Figure 5). By
contrast, there were no mutations ofCCND1 orCCND2 inMLL-
rearranged AML (n 5 56), suggesting that mutations of D-type
cyclins exhibit a subtype-specific pattern in AML.
Furthermore, we compared the messenger RNA expression levels
of CCND1, CCND2, and CCND3 between t(8;21) AML (n 5 60)
and MLL-rearranged AML (n 5 43) (in dataset GSE13159,
generated as part of the MILE [Microarray Innovations in LEukemia]
study program) using BloodSpot.39 CCND1 and CCND2 expres-
sion was significantly higher in t(8;21) AML than MLL-rearranged
AML (both P , .001), while CCND3 expression was significantly
higher in MLL-rearranged AML than t(8;21) AML (P , .001)
(Figure 2C). These data support the hypothesis that deregulation of
D-type cyclins exhibits a subtype-specific pattern in AML.
CDK4/6 inhibitors are a promising treatment of
MLL-rearranged AML
A recent study demonstrated that cancers with CCND3 amplifi-
cation may benefit from treatment with the CDK4/6 inhibitor
abemaciclib24; therefore, we examined whether CDK4/6 inhibitors
could be novel therapeutic agents for MLL-rearranged AML.
The effects of major CDK4/6 inhibitors (abemaciclib and
palbociclib) on the proliferation and cell-cycle progression of
MLL-rearranged AML cell lines (ML-2 [MLL-MLLT4 positive],
MV4-11 [MLL-AFF1 positive], MOLM-13 [MLL-MLLT3 positive],
THP-1 [MLL-MLLT3 positive], and NOMO-1 [MLL-MLLT3 posi-
tive]) were analyzed. The CDK4/6 inhibitor concentration
employed was 500 nM, based on previously published data.40
Among these cell lines, a CCND3 mutation (R271fs) was detected
Table 1. Characteristics of pediatric patients with MLL-rearranged



























FAB, French-American-British; ND, not determined; WBC, white blood cell count.
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in ML-2 cells by Sanger sequencing (supplemental Figure 4).
CCND3/cyclin D3 was highly expressed in MLL-rearranged
compared with t(8;21) AML cell lines (Kasumi-1 and SKNO-1)
(supplemental Figure 6). MLL-rearranged AML cell lines exhibited
impaired proliferation after treatment with CDK4/6 inhibitors
(Figure 3A). Furthermore, treatment of these cell lines with
CDK4/6 inhibitors resulted in detection of lower frequen-
cies of S/G2/M phase cells by flow cytometry, suggesting

























































Figure 1. Mutational landscape of pediatric MLL-rearranged AML. Driver or recurrent mutations and copy-number alterations observed in pediatric MLL-rearranged AML
(n 5 56). The frequencies of mutated genes are shown on the right. SNV, single-nucleotide variant; SV, structural variant.
Table 2. Characteristics of patients with MLL-rearranged AML and CCND3 mutation
Sample ID Age, y Sex Karyotype Exonic function AA change Mismatch rate Relapse Death
Childhood AML
AML05-120 11 M MLL-ELL Frameshift insertion exon5:c.811dupC p.R271fs 0.401 2 2
AML05-206 7 F MLL-MLLT3 Frameshift insertion exon5:c.811dupC p.R271fs 0.045 1 1
AML05-213 0 M MLL-MLLT10 Frameshift insertion exon5:c.836_837insAG p.S279fs 0.105 2 2
AML05-422 5 M MLL-ELL Frameshift insertion exon5:c.811dupC p.R271fs 0.479 1 2
AML05-426 1 F MLL-MLLT1 Frameshift deletion exon5:c.754_755delAG p.R252fs 0.022 2 2
Frameshift insertion exon5:c.757dupG p.E253fs 0.063
Frameshift insertion exon5:c.811dupC p.R271fs 0.040
Missense SNV exon5:c.C851G p.P284R 0.286
Adult AML
OT-034 66 M MLL-ELL Frameshift insertion exon5:c.811dupC p.R271fs 0.431 N/A N/A
07H003* 25 F MLL-ELL Frameshift insertion exon5:c.806dupC p.A269fs 0.282 N/A N/A
AA, amino acid; F, female; M, male; N/A, not available.
*Data for 07H003 were obtained by reanalysis of RNA-sequencing data reported in a previous study.18
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Next, we confirmed the role of cyclin D3 in MLL-rearranged AML
cells. Among the 5 MLL-rearranged AML cell lines, THP-1 was
selected because it could be knocked down efficiently by siRNA
(Figure 3D). THP-1 cells transfected with siRNA against the human
cyclin D3 transcript showed significant reductions in cell pro-
liferation and cell cycling from G1 to S phase compared with THP-1
cells transfected with nontargeting siRNA (Figure 3E-G). Taken
together, the results suggest that the cyclin D3-CDK4/6 complex
plays an important role in cell-cycle progression in MLL-rearranged
AML and that cyclin D3 and CDK4/6 are essential for the
mechanism (Figure 3H).
Coexisting mutations are associated with poor
prognosis in MLL-MLLT3–rearranged AML
Finally, we examined the prognostic significance of fusion partners
and coexisting mutations in pediatric MLL-rearranged AML.
Consistent with a previous report, patients with MLL-MLLT4
exhibited poor outcomes (Figure 4A).15 The relapse-free survival
(RFS) of patients with MLL-MLLT4 was significantly shorter than
that of those withMLL-MLLT3 (P5 .004),MLL-MLLT10 (P5 .001),
orMLL-ELL (P5 .002). Interestingly, patients with MLL-MLLT1 also
had poor outcomes, and the RFS of patients with this rearrangement
was significantly shorter than that of patients withMLL-ELL (P5 .03).
P values for comparisons between patients with each fusion subtype
are provided in supplemental Table 5.
We also evaluated the prognostic significance of coexisting
mutations identified in MLL-MLLT3–rearranged AML (n 5 25),
because this rearrangement was the most common in the cohort.
Patients with coexisting mutations listed in Figure 1 (n 5 16) had
significantly reduced RFS and overall survival (OS) compared with
those without coexisting mutations (n 5 9) (P 5 .048 and .046,
respectively) (Figure 4B). Investigation of the prognostic impact
of mutated pathways indicated that the RFS and OS of patients
with activated signaling mutations (FLT3, NRAS, KRAS, PTPN11,
CBL, and BRAF) tended to be shorter than those of patients
without such mutations; however, the difference was not statisti-
cally significant (supplemental Figure 7). We also analyzed the
prognostic significance of mutations of FLT3, CCND3, and RAS
pathway (NRAS, KRAS, PTPN11, and CBL), epigenetic regulator
(SETD2, ASXL1, ASXL2, BCOR, BCORL1, KDM6A, CREBBP,
and EP300), transcription factor (SPI1, WT1, MECOM, GATA2,
and RUNX1), and cohesin complex (STAG2, RAD21, and SMC3)
genes (supplemental Figure 8). No significant differences in
outcomes were associated with these mutation types. We also
analyzed the prognostic significance of coexisting mutations in other
subgroups (MLL-MLLT10, MLL-ELL, MLL-MLLT1, and MLL-
MLLT4); however, there were no significant differences (data not
shown). These analyses were limited by the small cohort size,
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Figure 2. CCND3 mutations in MLL-rearranged AML and
disease subtype–specific pattern of CCND1, CCND2,
and CCND3 mutations and expression. (A) Domain structure and
location of CCND3 mutations in pediatric and adult MLL-rearranged
AML. Lollipop plots were generated using ProteinPaint (https://pecan.
stjude.org/proteinpaint/). (B) Mutations of CCND1, CCND2, and
CCND3 in pediatric AML patients with t(8;21) and MLL rearrange-
ments (MLL-r). (C) Messenger RNA expression levels of CCND1,
CCND2, and CCND3 in t(8;21) AML (n 5 60) and MLL-rearranged
AML (n 5 43). ***P , .001.
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Discussion
In this study, we performed whole-exome sequencing of samples
from 9 pediatric patients with MLL-rearranged AML. The number of
mutations was smaller (mean, 5.8 mutations/patient) compared
with our previous findings from pediatric t(8;21) AML samples
(mean, 7.8 mutations/patient) (n 5 5)29 and data from a cohort of
pediatric core binding factor AML samples (mean, 7.4 mutations/
sample) (n5 87).22 This suggests that MLL fusion proteins require
fewer cooperating mutations than t(8;21) or inv(16).
We also performed targeted sequencing of 338 genes in 56 pediatric
MLL-rearranged AML. Among the detected mutations, alterations of
signaling pathway genes were the most frequently detected (34/56
patients; 60.7%), which is consistent with previous studies.16,17
A BRAF V600E mutation was detected in 1 patient. This mutation is
found in some types of cancer, including hairy cell leukemia, and is a
promising therapeutic target41; therefore, screening for the BRAF
V600E mutation should be considered in MLL-rearranged AML.
Patients with MLL-MLLT3-rearranged AML and coexisting mutations
had significantly worse RFS and OS. MLL-MLLT3–rearranged
AML is categorized as an intermediate-risk group15; therefore,
screening for coexisting mutations may enable improved risk
assessment for these patients. Previous studies failed to
determine the prognostic significance of coexisting mutations in
MLL-rearranged AML, which may be because of the limited numbers
of cases of each fusion partner included in the analyses.16,17
Further studies including larger numbers of patients are required.
We also observed recurrent mutations of epigenetic regulator genes
(SETD2,ASXL1,ASXL2,BCOR,BCORL1,KDM6A,CREBBP, and
EP300) in 12 patients (21.4%), suggesting that aberrant epigenetic
regulation is strongly involved in MLL-rearranged AML pathogenesis.
The result is not surprising, given its role as a histone methyl-
transferase. CREBBP and EP300 encode highly related acetyl-
transferases that act as transcriptional coactivators in multiple
signaling pathways.42 Recurrent mutations ofCREBBP and EP300
are reported in lymphomas and acute lymphoblastic leukemia (ALL);
however, few studies have identified these mutations in AML, except
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Figure 4. Prognostic significance of fusion partners in pediatric MLL-rearranged AML and coexisting mutations in pediatric MLL-MLLT3–rearranged AML.
(A) Comparison of patient RFS and OS according to MLL fusion partner. (B) Comparison of RFS and OS for patients with pediatric MLL-MLLT3–rearranged AML with and
without coexisting mutations. Survival estimates were compared using the log-rank test.
Figure 3. Effects of CDK4/6 inhibitors in MLL-rearranged AML cell lines. (A) Cell proliferation assay. ML-2, MV4-11, MOLM-13, THP-1, and NOMO-1 cells were
cultured in the presence of DMSO, palbociclib (500 nM), or abemaciclib (500 nM). (B) Cell-cycle analysis. Flow cytometric analysis of cell lines treated with DMSO,
palbociclib (500 nM), or abemaciclib (500 nM) for 24 hours and stained with propidium iodide. (C) Comparison of percentages of G2/M and S phase cells. (D) Immunoblot
analysis revealed significantly lower expression of cyclin D3 proteins in THP-1 cells transfected with siRNA against human cyclin D3 transcript (left column: siCCND3) than in
THP-1 cells transfected with non-targeting siRNA (right column: siControl). (E-G) THP-1 cells transfected with siCCND3 showed significant impairment in cell proliferation (E)
and cell-cycle progression from G1 to S phase (F-G) compared with those transfected with nontargeting siRNA. (H) Schematic figure showing that the cyclin D3-CDK4/6
complex promotes cell-cycle progression and CDK4/6 inhibitors are promising therapeutic agents in MLL-rearranged AML cells. Data are presented as the mean 6 standard
error of 3 independent experiments. ***P , .001, *P , .05.
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with the recurrent CCND3 mutations detected in this study, these
data indicate that MLL-rearranged AML may share some genetic
features with lymphomas and ALL.
Mutations in cohesin complex genes (STAG2, RAD21, and SMC3)
were detected in 5 patients (8.9%). Cohesin is a multimeric protein
complex composed of 4 subunits: STAG2, RAD21, SMC1A, and
SMC3.47 The frequency of mutations in cohesin complex genes is very
high in Down syndrome–related acute megakaryoblastic leukemia.48 In
de novo AML, the frequency of cohesin complex mutations is 10% to
12%,9,49 which is slightly higher than our findings for MLL-rearranged
AML; however,STAG2mutationswere detected in 3 patientswithMLL-
ELL, equating to a frequency of 30%. Furthermore, in a previous study
of adult MLL-rearranged AML, both STAG2 mutations identified were
also restricted to patients with MLL-ELL.18 Hence, although the
underlying mechanism is unclear, STAG2 mutations may have an
important role in the pathogenesis of MLL-ELL–rearranged AML.
We identified recurrent CCND3 mutations in pediatric and adult
MLL-rearranged AML. The frequency of CCND3 mutations in adult
patients (2/61; 3.3%) was lower than that in pediatric patients (5/56;
8.9%), which may be attributable to the different distribution of
translocation partners between these groups (Table 1; supplemental
Table 4). CCND3 mutations are well described in lymphoid
malignancies, including Burkitt lymphoma, diffuse large B-cell
lymphoma, follicular lymphoma, hairy cell leukemia variant (HCL-
V), splenic diffuse red pulp lymphoma, and T-lineage ALL.30,34-38
Nevertheless, there are few reports of CCND3 mutations in AML
other than 1 description of a case with normal karyotype AML and
CCND3 deletion.50 All CCND3 mutations detected in this study
were clustered in the region encoding the PEST domain, similar to
observations in lymphoid malignancies. CCND3 mutations affect-
ing the PEST domain cause stabilization of the cyclin D3 protein,
resulting in cell-cycle deregulation30; therefore, this mechanism may
be associated with the pathogenesis of MLL-rearranged AML, as well
as that of lymphoid malignancies. Mutation and overexpression of
CCND1, CCND2, and CCND3 exhibited an AML subtype–specific
pattern. In a previous study, selective use of D-type cyclins was revealed
in lymphoid malignancies by analysis of numerous cell lines51; however,
little is known about this phenomenon in AML. Our data suggest that
particular pairs of deregulated D-type cyclins and chromosomal
abnormalities may be associated with AML pathogenesis.
MLL-rearranged AML cell lines showed blocked G1 to S phase cell-
cycle progression and impaired proliferation after treatment with
CDK4/6 inhibitors (palbociclib and abemaciclib) (Figure 3). These
inhibitors are currently in clinical trials for treatment of multiple
cancers, including breast cancer and mantle cell lymphoma, and
some reports have already demonstrated that their use is linked to
improved survival rates.52-54 CCND3 amplification was recently
identified as a promising marker for predicting responses to CDK4/6
inhibitors.24,55 In this study, CDK4/6 inhibitors were effective in
inhibiting the growth of not only a CCND3-mutated cell line (ML-2)
but also that of cell lines lacking CCND3 mutations (MV4-11,
MOLM-13, THP-1, and NOMO-1). The MLL-rearrangement cell
lines without CCND3 mutations expressed abundant cyclin
D3 protein (supplemental Figure 6); therefore, CDK4/6 inhibitors
may be effective for the treatment of malignancies with these
characteristics. According to previous studies on other D-type
cyclins (CCND1 and CCND2),24,56 increased CCND3 expression
in cell lines withoutCCND3 mutations may be caused by mutations
or posttranscriptional modifications in 39 untranslated regions of
CCND3. According to the response profiles of abemaciclib across
560 reported cancer cell lines, ;20% of AML cells were sensitive;
however, the subtype of AML exhibiting sensitivity was not
discussed.24 This study revealed recurrent CCND3 mutations
and high CCND3 expression in MLL-rearranged AML patients;
therefore, CDK4/6 inhibitors represent a promising therapeutic
option, particularly for this patient subgroup. These data provide
further insights into the genetic basis of, and potential therapeutic
strategies for, MLL-rearranged AML.
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